Markets

Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima

Oct 5, 2026 · 07:32 AM ET· updated 1h ago

- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the

Why It Matters

BridgeBio shared test results showing their heart medicine helped patients. When you see this, watch if they finish their trial successfully.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BBIO67.00

-0.25 (-0.37%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.